Area of research
Surgery · Pulmonary and Respiratory Medicine
Research interest
Research interests include Bladder and Urothelial Cancer Treatments, Prostate Cancer Treatment and Research, Urinary and Genital Oncology Studies, and Prostate Cancer Diagnosis and Treatment.
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
The landscape of N6-methyladenosine in localized primary prostate cancer
The landscape of N<sup>6</sup>-methyladenosine in localized primary prostate cancer.
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
The Germline and Somatic Origins of Prostate Cancer Heterogeneity.
New insights into gut microbiota-prostate cancer crosstalk.
2025 Canadian Urological Association Expert Report: Muscle-invasive bladder cancer.
A versatile and efficient method to isolate nuclei from low-input cryopreserved tissues for single-nuclei transcriptomics.
Cisplatin- or Carboplatin-Based Chemotherapy Plus Pembrolizumab in Advanced Urothelial Cancer: Exploratory Analysis From the Phase 3 KEYNOTE-361 Study.
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative.
Poster Session 9: Oncology–Kidney, Testes, Penile : Sunday, June 29, 2025 • 07:00–08:30
2025cited by 0position: contributor
Poster Session 7: Oncology–Prostate (Part 2) : Sunday, June 29, 2025 • 07:00–08:30
2025cited by 0position: contributor
Ex vivo culture to evaluate dynamic changes in the tumor microenvironment following durvalumab treatment
Poster Session 3: Oncology–Bladder : Saturday, June 28, 2025 • 16:00–17:30
2025cited by 0position: contributor
Feasibility and acceptability of a personalised primary prevention strategy for women and men at high risk of breast and prostate cancer: the 3PC study protocol for a pilot randomised controlled trial.
Impact of Prior Chemotherapy on Response to Second-line Pembrolizumab in Urothelial Cancer: Exploratory Analysis of the Phase 3 KEYNOTE-045 Trial.
Figure 2 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 8 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 4 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 3 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 10 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 11 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 1 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 9 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Data from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Figure 3 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Supplementary Table 2 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Figure 5 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Figure 6 from The Germline and Somatic Origins of Prostate Cancer Heterogeneity